Last quarter (Q3 2023), Theseus Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Theseus Pharmaceuticals's net income was $-13.50M. See Theseus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 35.57M	$ -54.09M	$ -27.34M	$ 6.84M	$ 4.94M
Operating Income	$ -66.52M	$ -54.09M	$ -27.34M	$ -6.84M	$ -4.94M
Net Non Operating Interest Income Expense	-	-	-	-	-
Other Income Expense	$ -10.08M	$ -3.09M	$ -28.00K	$ -5.16M	$ -2.24M
Pretax Income	$ -56.45M	$ -50.99M	$ -27.31M	$ -12.00M	$ -7.18M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -99.56M	$ -101.60M	$ -54.62M	$ -12.00M	$ -7.18M
Basic EPS	$ -1.35	$ -1.31	$ -2.84	$ -1.01	$ -0.60
Diluted EPS	$ -1.35	$ -1.31	$ -2.84	$ -1.01	$ -0.60
Basic Average Shares	$ 168.40M	$ 38.49M	$ 9.63M	$ 11.92M	$ 11.92M
Diluted Average Shares	$ 168.40M	$ 38.49M	$ 9.63M	$ 11.92M	$ 11.92M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 35.57M	$ -54.09M	$ -27.34M	$ 6.84M	$ 4.94M
Net Income From Continuing And Discontinued Operation	$ -56.45M	$ -50.99M	$ -27.31M	$ -12.00M	$ -7.18M
Normalized Income	$ -22.36M	-	-	$ -12.00M	$ -7.18M
Interest Expense	-	-	-	-	-
EBIT	$ -56.45M	$ -50.99M	$ -27.31M	$ -6.84M	$ -4.94M
EBITDA	$ -44.56M	$ -51.60M	$ -27.31M	$ -6.83M	$ -4.94M

Currency in USD

Theseus Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing